Drug class
CD19-directed antibody-drug conjugate (ADC); pyrrolobenzodiazepine (PBD) alkylating antineoplastic
Mechanism of action
The anti-CD19 IgG1 antibody binds CD19 on B-lineage cells and is internalised. Proteolytic cleavage releases the SG3199 PBD dimer payload, which binds the DNA minor groove and forms interstrand crosslinks, leading to cell death.
General use cases
- Treatment of adults with relapsed or refractory large B-cell lymphoma after at least two prior systemic treatment lines, under the current product label.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
